JANSSEN PMP and LIPOFABRIK signed a global collaboration agreement to develop Mycosubtilin containing products

JANSSEN PMP, a division of Janssen Pharmaceutica NV, announced today the signature of a collaboration agreement with the French company Lipofabrik SAS specialized in the production, purification, formulation and marketing of lipopeptides. Janssen PMP will develop products containing Mycosubtilin, a patented lipopeptide from Lipofabrik SAS, to preserve fresh produce quality in the global market. Janssen PMP will develop for Post-Harvest, specific and fit-for-purpose formulations containing lipopeptides including Mycosubtilin. Preliminary trials showed a very strong activity of this natural compound allowing for extension of shelf life of harvested produce.“Signing this agreement is the beginning of a major strategic collaboration between our respective companies which will benefit the whole fruit industry” says Joan Jørgensen, General Manager of Janssen PMP. “The market is demanding efficient, natural solutions that can prevent the degradation and extend the shelf life of fruit”. “Lipofabrik will benefit from this close collaboration with Janssen PMP on technical, regulatory and commercial aspects” says Arnaud Delecroix, CEO of Lipofabrik SAS. “This agreement will contribute to bringing Lipofabrik to a next level in terms of business development”.About lipopeptides and MycosubtilinLipopeptides are molecules consisting of a lipid connected to a peptide. They are able to selfassemble into different structures. Many bacteria, such as Bacillus, produce these molecules as a part of their metabolism.The three main families of cyclic lipopeptides (surfactins, iturins and fengycins) are produced by the bacteria Bacillus subtilis. It has been proven that lipopeptides in general and Mycosubtilin (iturin family) in particular, are involved in Induced Systemic Resistance (ISR) activation, immune defence mechanisms against different aggressions and in resistance management to pathogens.About Lipofabrik SASLipofabrik is a start-up created in 2012 by three scientists from the University of Lille, with main activity on production, purification, composition and marketing of molecules of biological origin: the lipopeptides. These innovative and biodegradable molecules, derived from a proprietary strain of Bacillus subtilis, are produced by bioprocesses using renewable resources. Thanks to their surface-active, emulsifying, foaming and antifungal capacities, these lipopeptides find applications in various fields such as phytosanitary, cosmetics, detergency and disinfection. Expert in the working with Bacillus strains and lipopeptides, Lipofabrik has also developed a range of analyses that meet the strictest standards of traceability, reliability and precision. In constant development thanks to an R&D team at the cutting edge of innovation, Lipofabrik collaborates with numerous research organisations and develop its markets internationally.Contact:Arnaud Delecroix, CEOParc d'activités du Mélantois, 917 rue des saules, 59810 Lesquin, FRANCETel: +33 (0)3 20 86 74 60Mobile: +33 (0)6 26 60 40 45Email: arnaud.delecroix@lipofabrik.comAbout Janssen PMPJanssen PMP is a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.JANSSEN PMP is a long-established world leader in the development and formulation of new and highly effective active substances and end-use products for the protection of materials and food, especially fruits. With more than 50 years of experience in postharvest treatments of fruits globally, JANSSEN PMP has developed strong technical and commercial expertise. Through protection of our surroundings we aim to protect the health and well-being of the people in the environment in which our products are being used.Contact:Geoffroy de Chabot-Tramecourt, Director R&D and Business DevelopmentTurnhoutseweg 30, 2340 Beerse, BelgiumTel: +32 14 60 28 57Mobile: +32 471 80 82 09Email: gdchabot@its.jnj.com